The impact of biosimilars in the U.S. will be gradual. Drug-company investors should still be wary.
WSJ.com: Health, Wall Street Journal: Business: Health
Thu, 09/03/2015 - 3:52pm
The impact of biosimilars in the U.S. will be gradual. Drug-company investors should still be wary.